医学と薬学　77/7　2020年7月号

出版社： 自然科学社
発行日： 2020-06-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： パーキンソン病研究の最前線
電子書籍版： 2020-06-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　パーキンソン病研究の最前線

    序文
    パーキンソン病はアミロイドーシスか？
    パーキンソン病の動物モデル
    パーキンソン病のバイオマーカー
    α-シヌクレイノパチーにおけるプリオン様伝播：up to date
    家族性パーキンソン病の病理
    家族性パーキンソン病の最新治療
    パーキンソン病のiPSCs治療最前線

    Diagnosis
    　新しい血糖自己測定器の性能と操作性の評価
    　　―ISO15197に準じた検討―
    　安定心不全患者におけるBNP測定値の変化と心臓血管事故の関係および
    　　BNP測定試薬間差異の問題点
    　放射性免疫沈降法によるP/Q型電位依存性カルシウムチャネル抗体
    　　測定キットの基礎的・臨床的検討
    　評価評点方式を用いた定量的機種選定
    　　―全自動化学発光免疫測定装置Alinity®iの評価―
    　全自動生物化学発光免疫測定装置「BLEIA®-1200」
    　　専用試薬「BLEIA®‘栄研’ H.ピロリ抗原」の性能評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 パーキンソン病研究の最前線】

P.987 掲載の参考文献
1) Spillantini MG, Crowther RA, Jakes R, et al : α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95 (11) : 6469-6473, 1998.
 
2) Baba M, Nakajo S, Tu PH, et al : Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152 (4) : 879-884, 1998.
 
3) Luk KC, Kehm V, Carroll J, et al : Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338 (6109) : 949-953, 2012.
 
4) Masuda-Suzukake M, Nonaka T, Hosokawa M, et al : Prion-like spreading of pathological α-synuclein in brain. Brain 136 (Pt 4) : 1128-1138, 2013.
 
5) Araki K, Yagi N, Aoyama K, et al : Parkinson's disease is a type of amyloidosis featuring accumulation of amyloid fibrils of α-synuclein. Proc Natl Acad Sci USA 116 (36) : 17963-17969, 2019.
 
6) Araki K, Yagi N, Ikemoto Y, et al : Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson's disease patients. Sci Rep 5 : 17625, 2015.
PubMed
7) Mochizuki H, Choong CJ, Masliah E : A refined concept : α-synuclein dysregulation disease. Neurochem Int 119 : 84-96, 2018.
 
8) Iwai A, Masliah E, Yoshimoto M, et al : The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (2) : 467-475, 1995.
 
9) George JM, Jin H, Woods WS, et al : Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15 (2) : 361-372, 1995.
PubMed
10) Ueda K, Fukushima H, Masliah E, et al : Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90 (23) : 11282-11286, 1993.
PubMed
11) El-Agnaf OMA, Irvine GB : Review : Formation and properties of amyloid-like fibrils derived from α-synuclein and related proteins. J Struct Biol 130 (2-3) : 300-309, 2000.
 
12) Weinreb PH, Zhen W, Poon AW, et al : NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (43) : 13709-13715, 1996.
PubMed
13) Burre J, Sharma M, Sudhof TC : α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci USA 111 (40) : E4274-4283, 2014.
 
14) Lashuel HA, Petre BM, Wall J, et al : α-synuclein, especially the parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322 (5) : 1089-1102, 2002.
 
15) Wood SJ, Wypych J, Steavenson S, et al : α-Synuclein fibrillogenesis is nucleation-dependent : Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274 (28) : 19509-19512, 1999.
 
16) 荒木克哉, 望月秀樹, 八木直人 : パーキンソン病患者の剖検脳を用いた脳内凝集体に対する微細構造解析にて新たな疾患概念を提唱. Spring-8/SACLA Inf 25 : 2-5, 2020.
 
17) Fandrich M : On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci 64 (169) : 2066-2078, 2007.
 
18) Khurana R, Uversky VN, Nielsen L, et al : Is Congo Red an Amyloid-specific Dye? J Biol Chem 276 (25) : 22715-22721, 2001.
 
19) Arima K, Ueda K, Sunohara N, et al : Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 808 (1) : 93-100, 1998.
 
20) Takahashi H, Wakabayashi K : The cellular pathology of Parkinson's disease. Neuropathology 21 (4) : 315-322, 2001.
PubMed
21) Suzuki M, Sango K, Wada K, et al : Pathological role of lipid interaction with α-synuclein in Parkinson's disease. Neurochem Int 119 : 97-106, 2018.
 
22) Galvagnion C : The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson's Disease. J Parkinsons Dis 7 (3) : 433-450, 2017.
 
23) Serpell LC, Berriman J, Jakes R, et al : Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation. Proc Natl Acad Sci USA 97 (9) : 4897-4902, 2000.
 
24) Sipe JD, Benson MD, Buxbaum JN, et al : Nomenclature 2014 : Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 21 (4) : 221-224, 2014.
PubMed
P.995 掲載の参考文献
1) Davis GC, Williams AC, Markey SP, et al : Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1 (3) : 249-254, 1979.
PubMed
2) Langston JW, Ballard P, Tetrud JW, et al : Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (4587) : 979-980, 1983.
PubMed
3) Burns RS, Chiueh CC, Markey SP, et al : A primate model of parkinsonism : selective destruction of dopaminergic neurons in the pars compacta of the s ubstantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80 (14) : 4546-4550, 1983.
 
4) Mizuno Y, Suzuki K, Sone N : Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in mouse brain in vitro and in vivo. Adv Neurol 53 : 197-200, 1990.
PubMed
5) Marti Y, Matthaeus F, Lau T, et al : Methyl-4-phenylpyridinium (MPP+) dierentially aects monoamine release and re-uptake in murine embryonic stem cell-derived dopaminergic and serotonergicneurons. Mol. Cell. Neurosci 83 : 37-45, 2017.
 
6) Betarbet R, Sherer TB, MacKenzie G, et al : Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (12) : 1301-1306, 2000.
PubMed
7) Inden M, Kitamura Y, Abe M, et al : Parkinsonian rotenone mouse model : Reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull 34 : 92-96, 2011.
PubMed
8) Perese DA, Ulman J, Viola J, et al : 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 494 : 285-293, 1989.
PubMed
9) Le W, Sayana P, Jankovic J : Animal Models of Parkinson's Disease : A Gateway to Therapeutics? Neurotherapeutics 11 : 92-110, 2014.
PubMed
10) Polymeropoulos MH, Lavedan C, Leroy E, et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997.
PubMed
11) Singleton AB, Farrer M, J ohnson J, et al : alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 : 841, 2003.
 
12) Ibanez P, Bonnet AM, Debarges B, et al : Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364 : 1169-1171, 2004.
PubMed
13) Chartier-Harlin MC, Kachergus J, Roumier C, et al : Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 : 1167-1169, 2004.
PubMed
14) Kitada T, Asakawa S, Hattori N, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (6676) : 605-608, 1998.
 
15) Dawson TM, Ko HS, Dawson VL : Genetic animal models of Parkinson's disease. Neuron 66 : 646-661, 2010.
PubMed
16) Bonifati V, Rizzu P, van Baren MJ, et al : Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (5604) : 256-259, 2003.
 
17) Chen L, Cagniard B, Mathews T, et al : Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280 : 21418-21426, 2005.
PubMed
18) Funayama M, Hasegawa K, Kowa H, et al : A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51 (3) : 296-301, 2002
PubMed
19) Paisan-Ruiz C, Jain S, Evans EW, et al : Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (4) : 595-600, 2004.
PubMed
20) Zimprich A, Biskup S, Leitner P, et al : Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (4) : 601-607, 2004.
PubMed
21) Li Y, Liu W, Oo TF, et al : Mutant LRRK2 (R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12 : 826-828, 2009.
 
22) Braak H, Tredici KH, Rub U, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 24 : 197-211, 2003.
 
23) Richfield EK, Thiruchelvam MJ, Deborah A, et al : Behavioral and neurochemical effects of wild-type and mutated human α-synuclein in transgenic mice. Exp Neurol 175 : 35-48, 2002.
 
24) Rathke-Hartlieb S, Kahle PJ, Neumann M, et al : Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant α-synuclein transgenic mice. Neurochem 77 : 1181-1184, 2001.
 
25) Matsuoka Y, Vila M, Lincoln S, et al : Lack of nigral pathology in transgenic mice expressing human α-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis 8 : 535-539, 2001.
 
26) Thiruchelvam MJ, Powers JM, Cory-Slechta DA, et al : Risk factors for dopaminergic neuron loss in human α-synuclein transgenic mice. Eur J Neurosci 19 : 845-854, 2004.
 
27) Tofaris GK, Garcia Reitbock P, Humby T, et al : Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human α-synuclein (1-120) : implications for Lewy body disorders. J Neurosci 26 (15) : 3942-3950, 2006.
 
28) Wakamatsu M, Ishii A, Iwata S, et al : Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein in mice. Neurobiol Aging 29 (4) : 574-585, 2008
 
29) Rockenstein E, Mallory M, Hashimoto M, et al : Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and thy-1 promoters. J Neurosci Res 68 : 568-578, 2002.
 
30) Neuman M. Kahle PJ, Giasson BI, et al : Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration. J Clin Invest 110 (10) : 1429-1439, 2002.
 
31) van der Putten H, Wiederhold KH, Probstet A, et al : Neuropathology in mice expressing human α-synuclein. J Neurosci 20 (16) : 6021-6029, 2000.
 
32) Kahle PJ, Neumann M, Ozmen L, et al : Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159 (6) : 2215-2225, 2001.
 
33) Giasson BI, Duda JE, Quinn SM, et al : Neuronal alpha-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-synuclein. Neuron 34 : 521-533, 2002.
 
34) Yamakado H, Moriwaki Y, Yamasaki N, et al : α-synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior and hyperlocomotion. Neurosci Res 73 (2) : 173-177, 2012.
 
35) Taguchi T, Ikuno M, Hondo M, et al : α-synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia : a prodromal Parkinson's disease model. Brain 143 (1) : 249-265, 2020.
 
36) Masuda-Suzukake M, Nonaka T, Hosokawa M, et al : Prion-like spreading of pathological α-synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia : a prodromal Parkinson's disease model in brain. Brain 136 : 1128-1138, 2013.
 
37) Hayakawa H, Nakatani R, Ikenaka K, et al : Structurally distinct α-synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia : a prodromal Parkinson's disease model fibrils induce robust parkinsonian pathology. Mov Disord 35 (2) : 256-267, 2020.
 
38) Eslamboli A : Marmoset monkey models of Parkinson's disease : which model, when and why? Brain Res Bull 68 (3) : 140-149, 2005.
PubMed
39) Yun JW, Ahn JB, Kang BC : Modeling Parkinson's disease in the common marmoset (Callithrix jacchus) : overview of models, methods, and animal care. Lab Anim Res 31 (4) : 155-165, 2015.
PubMed
40) Okano H, Sasaki E, Yamamori T, et al : Brain/MINDS : A Japanese National Brain Project for Marmoset Neuroscience. Neuron 92 (3) : 582-590, 2016.
PubMed
41) Kirik D, Annett LE, Burger C, et al : Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein : a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 100 (5) : 2884-2889, 2003.
PubMed
42) Shimozawa A, Ono M, Takahara D, et al : Propagation of pathological α-synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia : a prodromal Parkinson's disease model in marmoset brain. Acta Neuropathol Commun 5 (1) : 12, 2017.
 
43) Martinez BA, Caldwell KA., Caldwell GA : C. elegans as a model system to accelerate discovery for Parkinson disease. Curr Opin Genet Dev 44 : 102-109, 2017.
 
44) Lakso M, Vartiainen S, Moilanen, AM, et al : Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human αsyn. J Neurochem 86 (1) : 165-172, 2003.
 
45) Van Ham TJ, Thijssen KL, Breitling R, et al : C. elegans model identifies genetic modifiers of α-synuclein inclusion formation during aging. PLoS Genet 4 (3) : e1000027, 2008
 
46) Tyson T, Senchuk M, Cooper JF, et al : Novel animal model defines genetic contributions for neuron-to-neuron transfer of α-synuclein. Sci Rep 7 : 7506, 2017.
 
47) Shukla AK, Pragya P, Chaouhan HS, et al : Mutation in Drosophila methuselah resists paraquat induced Parkinson-like phenotypes. Neurobiol Aging 35 (10) : 2419.e1-2419.e16, 2014.
 
48) Feany MB, Bender WW : A Drosophila model of Parkinson's disease. Nature 404 (6776) : 394-398, 2000.
PubMed
49) Sakai R, Suzuki M, Ueyama M, et al : E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease. PLoS One 14 (6) : e0218261, 2019.
 
P.1005 掲載の参考文献
1) Hughes AJ, Daniel SE, Lees AJ : Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 (8) : 1497-1499. 2001.
PubMed
2) Hughes AJ, Daniel SE, Kilford L, et al : Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55 (3) : 181-184, 1992.
 
3) Araki K, Yagi N, Aoyama K, et al : Parkinson's disease is a type of amyloidosis featuring accumulation of amyloid fibrils of alpha-synuclein. Proc Natl Acad Sci USA 116 (36) : 17963-17969, 2019.
PubMed
4) Araki K, Yagi N, Ikemoto Y, et al : Synchrotron FTIR micro-spectroscopy for structural analysis of Lewy bodies in the brain of Parkinson's disease patients. Sci Rep 5 : 17625, 2015.
PubMed
5) Hayakawa H, Nakatani R, Ikenaka K, et al : Structurally distinct alpha-synuclein fibrils induce robust parkinsonian pathology. Mov Disord 35 (2) : 256-267, 2020.
PubMed
6) Tokuda T, Salem SA, Allsop D, et al : Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349 (1) : 162-166, 2006.
PubMed
7) Eusebi P, Giannandrea D, Biscetti L, et al : Diagnostic utility of cerebrospinal fluid alpha-synuclein in Parkinson's disease : A systematic review and meta-analysis. Mov Disord 32 (10) : 1389-1400, 2017.
PubMed
8) Mollenhauer B, Caspell-Garcia CJ, Coffey CS, et al : Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology 89 (19) : 1959-1969, 2017.
 
9) Mollenhauer B, Zimmermann J, Sixel-Doring F, et al : Monitoring of 30 marker candidates in early Parkinson disease as progression markers. Neurology 87 (2) : 168-177, 2016.
PubMed
10) Tokuda T, Qureshi MM, Ardah MT, et al : Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75 (20) : 1766-1772, 2010.
PubMed
11) Park MJ, Cheon SM, Bae HR, et al : Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 7 (4) : 215-222, 2011.
PubMed
12) Sakakibara R, Tateno F, Kishi M, et al : MIBG myocardial scintigraphy in pre-motor Parkinson's disease : a review. Parkinsonism Relat Disord 20 (3) : 267-273, 2014.
PubMed
13) Groveman BR, Orru CD, Hughson AG, et al : Rapid and ultra-sensitive quantitation of disease-associated alpha-synuclein seeds in brain and cerebrospinal fluid by alphaSyn RT-QuIC. Acta Neuropathol Commun 6 (1) : 7, 2018.
PubMed
14) Shahnawaz M, Tokuda T, Waragai M, et al : Development of a Biochemical Diagnosis of Parkinson Disease by Detection of alpha-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol 74 (2) : 163-172, 2017.
PubMed
15) Fairfoul G, McGuire LI, Pal S, et al : Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3 (10) : 812-818, 2016.
PubMed
16) Shahnawaz M, Mukherjee A, Pritzkow S, et al : Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy. Nature 578 (7794) : 273-277, 2020.
PubMed
17) Kang UJ, Boehme AK, Fairfoul G, et al : Comparative study of cerebrospinal fluid alpha-synuclein seeding aggregation assays for diagnosis of Parkinoson's disease. Mov Disord 34 (4) : 536-544, 2019.
PubMed
18) Kakuda K, Ikenaka K, Araki K, et al : Ultrasonication-based rapid amplification of alpha-synuclein aggregates in cerebrospinal fluid. Sci Rep 9 (1) : 6001, 2019.
PubMed
19) Campo F, Carletti R, Fusconi M, et al : Alphasynuclein in salivary gland as biomarker for Parkinson's disease. Rev Neurosci 30 (5) : 455-462, 2019.
PubMed
20) Manne S, Kondru N, Jin H, et al : alpha-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients. Mov Disord 35 (2) : 268-278, 2020.
PubMed
21) Schepici G, Silvestro S, Trubiani O, et al : Salivary Biomarkers : Future Approaches for Early Diagnosis of Neurodegenerative Diseases. Brain Sci 10 (4) : pii : E245, 2020.
 
22) De Luca CMG, Elia AE, Portaleone SM, et al : Efficient RT-QuIC seeding activity for alpha-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy. Transl Neurodegener 8 : 24, 2019
PubMed
23) Nuzhnyi E, Emelyanov A, Boukina T, et al : Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease. Mov Disord 30 (7) : 989-991, 2015.
PubMed
24) Moors T, Paciotti S, Chiasserini D, et al : Lysosomal Dysfunction and alpha-Synuclein Aggregation in Parkinson's Disease : Diagnostic Links. Mov Disord 31 (6) : 791-801, 2016.
PubMed
25) Parnetti L, Chiasserini D, Persichetti E, et al : Cerebrospinal fluid lysosomal enzymes and alphasynuclein in Parkinson's disease. Mov Disord 29 (8) : 1019-1027, 2014.
PubMed
26) Parnetti L, Balducci C, Pierguidi L, et al : Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. Neurobiol Dis 34 (3) : 484-486, 2009.
PubMed
27) Balducci C, Pierguidi L, Persichetti E, et al : Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord 22 (10) : 1481-1484, 2007.
PubMed
28) Parnetti L, Paciotti S, Eusebi P, et al : Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in parkinson's disease patients. Mov Disord 32 (10) : 1423-1431., 2017.
PubMed
29) Atashrazm F, Hammond D, Perera G, et al : Reduced glucocerebrosidase activity in monocytes from patients with Parkinson's disease. Sci Rep 8 (1) : 15446, 2018.
PubMed
30) Fraser KB, Moehle MS, Alcalay RN, et al : Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. Neurology 86 (11) : 994-999, 2016.
PubMed
31) Wang S, Liu Z, Ye T, et al : Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathol Commun 5 (1) : 86, 2017.
 
32) Fraser KB, Rawlins AB, Clark RG, et al : Ser (P) -1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Mov Disord 31 (10) : 1543-1550, 2016.
 
33) Espay AJ, Kalia LV, Gan-Or Z, et al : Disease modification and biomarker development in Parkinson disease : Revision or reconstruction? Neurology 94 (11) : 481-494, 2020.
PubMed
34) Saiki S, Sasazawa Y, Fujimaki M, et al : A metabolic profile of polyamines in parkinson disease : A promising biomarker. Ann Neurol 86 (2) : 251-263, 2019.
PubMed
P.1013 掲載の参考文献
1) Goedert M : Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2 (7) : 492-501, 2001.
PubMed
2) Polymeropoulos MH, Lavedan C, Leroy E, et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (5321) : 2045-2047, 1997.
PubMed
3) Nussbaum RL : Genetics of Synucleinopathies. Cold Spring Harb Perspect Med 8 (6) : a024109, 2018
PubMed
4) Singleton AB, F arrer M, Johnson J, et al : alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (5646) : 841, 2003.
 
5) Burre J, Sharma M, Sudhof TC : Cell Biology and Pathophysiology of alpha-Synuclein. Cold Spring Harb Perspect Med 8 (3) : a024091, 2018.
PubMed
6) Tarutani A, Arai T, Murayama S et al : Potent prion-like behaviors of pathogenic alpha-synuclein and evaluation of inactivation methods. Acta Neuropathol Commun 6 (1) : 29, 2018.
PubMed
7) Araki K, Yagi N, Aoyama K, et al : Parkinson's disease is a type of amyloidosis featuring accumulation of amyloid fibrils of alpha-synuclein. Proc Natl Acad Sci USA 116 (36) : 17963-17969, 2019.
PubMed
8) Fujiwara H, Hasegawa M, Dohmae N, et al : alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4 (2) : 160-164, 2002.
PubMed
9) Hasegawa M, Fujiwara H, Nonaka T, et al : Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem 277 (50) : 49071-49076, 2002.
PubMed
10) Prusiner SB : Novel proteinaceous infectious particles cause scrapie. Science 216 (4542) : 136-144, 1982.
PubMed
11) Braak H, Del Tredici K, Rub U et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2) : 197-211, 2003.
PubMed
12) Saito Y, Kawashima A, Ruberu NN, et al : Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 62 (6) : 644-654, 2003.
 
13) Kordower JH, Chu Y, Hauser RA, et al : Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (5) : 504-506, 2008.
PubMed
14) Li JY, Englund E, Holton JL, et al : Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 (5) : 501-503, 2008.
PubMed
15) Hasegawa M, Nonaka T, Masuda-Suzukake M : alpha-Synuclein : Experimental Pathology. Cold Spring Harb Perspect Med 6 (9) : a024273, 2016.
PubMed
16) Nonaka T, Watanabe ST, Iwatsubo T, et al : Seeded aggregation and toxicity of alpha-synuclein and tau : cellular models of neurodegenerative diseases. J Biol Chem 285 (45) : 34885-34898, 2010.
PubMed
17) Volpicelli-Daley LA, Luk KC, Patel TP, et al : Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72 (1) : 57-71, 2011.
PubMed
18) Masuda-Suzukake M, Nonaka T, Hosokawa M, et al : Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun 2 : 88, 2014.
PubMed
19) Rey NL, Steiner JA, Maroof N, et al : Widespread transneuronal propagation of alpha-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. J Exp Med 213 (9) : 1759-1778, 2016.
PubMed
20) Henderson MX, Cornblath EJ, Darwich A, et al : Spread of alpha-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat Neurosci 22 (8) : 1248-1257, 2019.
PubMed
21) Masuda-Suzukake M, Nonaka T, Hosokawa M, et al : Prion-like spreading of pathological alpha-synuclein in brain. Brain 136 (Pt 4) : 1128-1138, 2013.
 
22) Shimozawa A, Ono M, Takahara D, et al : Propagation of pathological alpha-synuclein in marmoset brain. Acta Neuropathol Commun 5 (1) : 12, 2017.
PubMed
23) Chu Y, Muller S, Tavares A, et al : Intrastriatal alpha-synuclein fibrils in monkeys : spreading, imaging and neuropathological changes. Brain 142 (11) : 3565-3579, 2019.
PubMed
24) Manfredsson FP, Luk KC, Benskey MJ, et al : Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis 112 : 106-118, 2018.
PubMed
25) Uemura N, Yagi H, Uemura MT et al : Inoculation of alpha-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy bodylike aggregates in the brainstem via the vagus nerve. Mol Neurodegener 13 (1) : 21, 2018.
PubMed
26) Kim S, Kwon SH, Kam TI, et al : Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson's Disease. Neuron 103 (4) : 627-641, 2019.
 
27) Challis C, Hori A, Sampson TR, et al : Gut-seeded alpha-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat Neurosci 23 (3) : 327-336, 2020.
PubMed
28) Soto C, Saborio GP, Anderes L : Cyclic amplification of protein misfolding : application to prion-related disorders and beyond. Trends Neurosci 25 (8) : 390-394, 2002.
PubMed
29) Kakuda K, Ikenaka K, Araki K, et al : Ultrasonication-based rapid amplification of alpha-synuclein aggregates in cerebrospinal fluid. Sci Rep 9 (1) : 6001, 2019.
PubMed
30) Fairfoul G, McGuire LI, Pal S, et al : Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol 3 (10) : 812-818, 2016.
PubMed
31) Sano K, Atarashi R, Satoh K, et al : Prion-Like Seeding of Misfolded alpha-Synuclein in the Brains of Dementia with Lewy Body Patients in RT-QUIC. Mol Neurobiol 55 (5) : 3916-3930, 2018.
PubMed
32) Shahnawaz M, Tokuda T, Waragai M, et al : Development of a Biochemical Diagnosis of Parkinson Disease by Detection of alpha-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA Neurol 74 (2) : 163-172, 2017.
PubMed
33) Tran HT, Chung CH, Iba M, et al : Alpha-synuclein immunotherapy blocks uptake and templated propagation of misfolded alpha-synuclein and neurodegeneration. Cell Rep 7 (6) : 2054-2065, 2014.
PubMed
34) Luna E, Decker SC, Riddle DM, et al : Differential alpha-synuclein expression contributes to selective vulnerability of hippocampal neuron subpopulations to fibril-induced toxicity. Acta Neuropathol 135 (6) : 855-875, 2018.
PubMed
35) Shimozawa A, Fujita Y, Kondo H, et al : Effect of L-DOPA/Benserazide on Propagation of Pathological alpha-Synuclein. Front Neurosci 13 : 595, 2019.
PubMed
36) Peelaerts W, Bousset L, Van der Perren A, et al : alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522 (7556) : 340-344, 2015.
PubMed
37) Prusiner SB, Woerman AL, Mordes DA, et al : Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci USA 112 (38) : E5308-5317, 2015.
PubMed
38) Peng C, Gathagan RJ, Covell DJ, et al : Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature 557 (7706) : 558-563, 2018.
PubMed
39) Miller DW, Johnson JM, Solano SM et al : Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm (Vienna) 112 (12) : 1613-1624, 2005.
PubMed
40) Asi YT, Simpson JE, Heath PR, et al : Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 62 (6) : 964-970, 2014.
PubMed
41) Schweighauser M, Shi Y, Tarutani A, et al : Structures of alpha-synuclein filaments from multiple system atrophy. bioRxiv, 2020.
 
42) Abounit S, Bousset L, Loria F, et al : Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. EMBO J 35 (19) : 2120-2138, 2016.
 
P.1022 掲載の参考文献
1) Farrer M, Kachergus J, Forno L, et al : Comparison of kindreds with parkinsonism and alpha-synuclein genomic multi-plications. Ann Neurol 55 : 174-179, 2004.
 
2) Obi T, Nishioka K, Ross OA, et al : Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70 : 238-241, 2008.
PubMed
3) 高齢者ブレインバンクホームページ : www.mci.gr.jp/BrainBank/ (2020年6月15日アクセス).
 
P.1029 掲載の参考文献
1) GBD 2016 Parkinson's Disease Collaborators : Global, regional, and national burden of Parkinson's disease, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17 (11) : 939-953, 2018.
PubMed
2) Dorsey ER, Bloem BR : The Parkinson pandemic-A call to action. JAMA Neurol 75 (1) : 9-10, 2018.
 
3) Kalia LV, Lang AE : Parkinson's disease. Lancet 386 (9996) : 896-912, 2015.
PubMed
4) Braak H, Del Tredici K, Rub U, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2) : 197-211, 2003.
PubMed
5) Goedert M, Spillantini MG, Del Tredici K, et al : 100 years of Lewy pathology. Nat Rev Neurol 9 (1) : 13-24, 2013.
PubMed
6) Nalls MA, Blauwendraat C, Vallerga CL, et al : Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease : a meta-analysis of genome-wide association studies. Lancet Neurol 18 (12) : 1091-1102, 2019.
PubMed
7) Blauwendraat C, Nalls MA, Singleton AB : The genetic architecture of Parkinson's disease. Lancet Neurol 19 (2) : 170-178, 2020.
 
8) Schneider SA, Alcalay RN : Precision medicine in Parkinson's disease : emerging treatments for genetic Parkinson's disease. J Neurol 267 (3) : 860-869, 2020.
PubMed
9) Lill CM : Genetics of Parkinson's disease. Mol Cell Probes 30 (6) : 386-396, 2016.
PubMed
10) Alves G, Muller B, Herlofson K, et al : Incidence of Parkinson's disease in Norway : the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 80 (8) : 851-857, 2009.
PubMed
11) Araki K, Sugawara K, Hayakawa EH, et al : The localization of α-synuclein in the process of differentiation of human erythroid cells. Int J Hematol 108 (2) : 130-138, 2018.
 
12) Bernal-Conde LD, Ramos-Acevedo R, Reyes-Hernandez MA, et al : Alpha-synuclein physiology and pathology : A perspective on cellular structures and organelles. Front Neurosci 13 : 1399, 2020.
 
13) Polymeropoulos MH, Lavedan C, Leroy E, et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (5321) : 2045-2047, 1997.
PubMed
14) Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 388 (6645) : 839-840, 1997.
PubMed
15) Singleton AB, Farrer M, Johnson J, et al : Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 : 841, 2003.
PubMed
16) Nakamori M, Junn E, Mochizuki H, et al : Nucleic acid-based therapeutics for Parkinson's disease. Neurotherapeutics 16 (2) : 287-298, 2019.
PubMed
17) Kordower JH, Chu Y, Hauser RA, et al : ewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 (5) : 504-506, 2008.
 
18) Li W, Englund E, Widner H, et al : Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc Natl Acad Sci USA 113 (23) : 6544-6549, 2016.
PubMed
19) Henderson MX, Cornblath EJ, Darwich A, et al : Spread of α-synuclein pathology through the brain connectome is modulated by selective vulnerability and predicted by network analysis. Nat Neurosci 22 (8) : 1248-1257, 2019.
 
20) Teil M, Arotcarena ML, Faggiani E, et al : Targeting α-synuclein for PD Therapeutics : A Pursuit on All Fronts. Biomolecules 10 (3) : 391, 2020
 
21) Kang L, Wu KP, Vendruscolo M, et al : The A53T mutation is key in defining the differences in the aggregation kinetics of human and mouse α-synuclein. J Am Chem Soc 133 (34) : 13465-13470, 2011.
 
22) Chatterjee D, Kordower JH : Immunotherapy in Parkinson's disease : Current status and future directions. Neurobiol Dis 132 : 104587, 2019.
PubMed
23) Mandler M, Valera E, Rochenstein E, et al : Next-generation active immunization approach for synucleinopathies : implications for Parkinson's disease clinical trials. Acta neuropathol 127 : 861-879, 2014.
 
24) Masliah E, Rockenstein E, Mante M, et al : Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6 (4) : e19338, 2011.
 
25) Schenk DB, Koller M, Ness DK, et al : First-inhuman assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers. Mov Disord 32 (2) : 211-218, 2017.
 
26) Jankovic J, Goodman I, Safirstein B, et al : Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease : A randomized clinical trial. JAMA Neurol 75 (10) : 1206-1214, 2018.
 
27) Weihofen A, Liu Y, Arndt JW, et al : Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiol Dis 124 : 276-288, 2019.
 
28) Uehara T, Choong CJ, Nakamori M, et al : Amido-bridged nucleic acid (AmNA) -modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson's disease. Sci Rep 9 (1) : 7567, 2019.
 
29) Berwick DC, Heaton GR, Azeggagh S, et al : LRRK2 Biology from structure to dysfunction : research progresses, but the themes remain the same. Mol Neurodegener 14 (1) : 49, 2019.
PubMed
30) Di Maio R, Hoffman EK, Rocha EM, et al : LRRK2 activation in idiopathic Parkinson's disease. Sci Transl Med 10 (451) : eaar5429, 2018.
PubMed
31) Blandini F, Cilia R, Cerri S, et al. Glucocerebrosidase mutations and synucleinopathies : Toward a model of precision medicine. Mov Disord 34 (1) : 9-21, 2019.
 
32) Ysselstein D, Nguyen M, Young TJ, et al : LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients. Nat Commun 10 (1) : 5570, 2019.
PubMed
33) Saxton RA, Sabatini DM : mTOR Signaling in Growth, Metabolism, and Disease. Cell 168 (6) : 960-976, 2017.
PubMed
34) Grieco M, Giorgi A, Gentile MC, et al : Glucagon-Like Peptide-1 : A Focus on Neurodegenerative Diseases. Front Neurosci 13 : 1112, 2019.
PubMed
35) Yun SP, Kam TI, Panicker N, et al : Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease. Nat Med 24 (7) : 931-938, 2018.
PubMed
36) Ko HS, Lee Y, Shin JH, et al : Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci USA 107 (38) : 16691-16696, 2010.
 
37) Elsworth JD : Parkinson's disease treatment : past, present, and future. J Neural Transm (Vienna), 2020. https://doi.org/10.1007/s00702-020-02167-1 [Epub ahead of print]
 
38) Kimura Y, Shofuda T, Higuchi Y, et al : Human Genomic Safe harbors and the suicide gene-based safeguard system for iPSC-based cell therapy. Stem Cells Transl Med 8 (7) : 627-638, 2019.
PubMed
39) Fan Y, Winanto, Ng SY : Replacing what's lost : a new era of stem cell therapy for Parkinson's disease. Transl Neurodegener 9 : 2, 2020.
 
P.1037 掲載の参考文献
1) Takahashi K, Yamanaka S : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (4) : 663-676, 2006.
PubMed
2) Takahashi K, Tanabe K, Ohnuki M, et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (5) : 861-872, 2007.
PubMed
3) Gurdon JB : The Developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 10 : 622-640, 1962.
PubMed
4) Tabata T, Imaizumi Y, Sugawara M, et al : T-type calcium channels determine the vulnerability of dopaminergic neurons to mitochondrial stress in familial Parkinson disease. Stem Cell Reports 11 (5) : 1171-1184, 2018.
 
5) Imamura K, Izumi Y, Watanabe Akira, et al : The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 9 (391) : eaaf3962, 2017.
PubMed
6) Fujimori K, Ishikawa Mitsuru, Otomo A, et al : Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med 24 (10) : 1579-1589, 2018.
PubMed
7) Kondo T, Imamura K, Funayama M, et al : iPSC-based compound screening and in vitro trials identify a synergistic anti-amyloid β combination for Alzheimer's disease. Cell Rep 21 (8) : 2304-2312, 2017.
 
8) Evans MJ, Kaufman MH : Establishment in culture of pluripotential cells from mouse embryos. Nature 292 (5819) : 154-156, 1981.
PubMed
9) Martin GR : Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci USA 78 (12) : 7634-7638, 1981.
PubMed
10) Morizane A, Doi D, Kikuchi T, et al : Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports 1 (4) : 283-292, 2013.
PubMed
11) Xu H, Wang B, Ono M, et al : Targeted disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24 (4) : 566-578.e7, 2019.
 
12) Parkinson J : An Essay on the Shaking Palsy. London : Whittingham and Rowland for Sherwood, Neely, and Jones, 1817.
 
13) Gilles de la Tourette G : Considerations sur la medecine vibratoire et ses applications et sa technique. Nouv Icon Salpetriere 5 : 265-275, 1892.
 
14) Ordenstein L : Sur la paralysie agitante et la sclerose en plaques generalisee. A. Delahaye, 1868.
 
15) 佐野勇 : 錐体外路系の生化学. 神経研究の進歩 5 (1) : 42-48, 1960.
 
16) Ehringer H, Hornykiewicz O : Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 38 : 1236-1239, 1960.
PubMed
17) Cotzias GC : L-Dopa for parkinsonism. N Engl J Med 278 (11) : 630, 1968.
PubMed
18) Yahr MD, Duvoisin RC, Schear MJ, et al : Treatment of parkinsonism with levodopa. Arch Neurol 21 (4) : 343-354, 1969.
PubMed
19) Poewe WH, Wenning GK : The natural history of Parkinson's disease. Neurology 47 (6 Suppl 3) : S146-152, 1996.
 
20) Lindvall O, Rehncrona S, Brundin P, et al : Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46 (6) : 615-631, 1989.
 
21) Freed CR, Greene PE, Breeze RE, et al : Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (10) : 710-719, 2001.
PubMed
22) Olanow CW, Goetz CG, Kordower JH, et al : A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (3) : 403-414, 2003.
PubMed
23) Barker RA, TRANSEURO consortium : Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nat Med 25 (7) : 1045-1053, 2019.
PubMed
24) Barker RA, Parmar M, Studer L, et al : Human trials of stem cell-derived dopamine neurons for Parkinson's disease : dawn of a new era. Cell Stem Cell 21 (5) : 569-573, 2017.
PubMed
25) Doi D, Samata Bu, Katsukawa M, et al : Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports 2 (3) : 337-350, 2014.
 
26) Kikuchi T, Morizane A, Doi D, et al : Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 548 (7669) : 592-596, 2017.
 
27) Kalia LV, Lang AE : Parkinson's disease. Lancet 386 (9996) : 896-912, 2015.
PubMed
28) Braak H, Tredici KD, Rub U, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2) : 197-211, 2003.
 
29) Li JY, Englund E, Holton JL, et al : Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 (5) : 501-503, 2008.
PubMed

【Diagnosis】

P.1048 掲載の参考文献
1) 日本糖尿病学会 : フラッシュグルコースモニタリング (FGM) システム : FreeStyleリブレに関する見解 (改訂), 日本糖尿病学会, 2019. 4.12発行
 
2) ISO15197 : In vitro diagnostic test systems-requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus, 2013.
 
3) Joan L. Parkes, et al : A New Consensus Error Grid to Evaluate the Clinical Significance of Inaccuracies in the Measurement of Blood Glucose. Diabetes Care 23 (8) : 1143-1148, 2000.
 
4) 宇佐美勝, 池田弘毅, 池田正毅, 他 : カラー液晶を有する新しい血糖自己測定器の性能と操作性の評価-ISO15197に準じた検討. 医療と検査機器・試薬 36 (2) : 207-216, 2013.
Medical*Online
5) 道口佐多子, 遅野井健 : 新しい血糖自己測定器の性能と操作性について-ISO15197 : 2013にもとづいた検討と評価結果-. 医療と検査機器・試薬 40 (3) : 237-244, 2017.
Medical*Online
6) 井島廣子, 陣内秀昭, 他 : グルコカード プラスケアの基礎性能評価. 医療と検査機器・試薬 42 (2) : 132-138, 2019.
Medical*Online
7) 木村那智 : SMBGにおけるPC, スマートフォンの活用. 糖尿病診療マスター 13 (9) : 744-748, 2015.
 
8) 小出景子 : 薬剤師の立場からSMBGデータをどう読むか. DM Ensemble 6 (3) : 12-14, 2017.
 
9) 小出景子, 渥美義仁 : スマートフォンで食事・ウォーキング・血糖・注射を把握する療養指導. 月刊糖尿病 9 (1) : 47-57, 2017.
 
10) 残松直樹 : せんせい教えてください!. さかえ 59 (10) : 52-53, 2019.
 
P.1055 掲載の参考文献
1) Yancy CW, et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 23 (8) : 628-651, 2017.
 
2) 慢性心不全治療ガイドライン (2018年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf.
 
3) Tsutamoto T, et al : Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure : prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 : 509-516, 1997.
PubMed
4) 蔦本尚慶, 斉藤能彦 : 新BNPと日常診療-心機能異常の早期発見のために. 南江堂, 東京, 2005.
 
5) Januzzi JL, et al : NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure : an international pooled analysis of 1256 patients : the International Collaborative of NT-proBNP Study. Eur Heart J 27 (3) : 330-337, 2006.
 
6) Maeda K, et al : Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135 : 825-832, 1998.
PubMed
7) Collin-Chavagnac D, et al : Head-to-head comparison of 10 natriuretic peptide assay. Clin Chem Lab Med 53 (11) : 1825-1837, 2015.
PubMed
8) 福岡達仁, 他 : ケミルミADVIA Centaur XPによる心筋バイオマーカーの基礎的検討. 医学と薬学 63 (4) : 651-657, 2010.
Medical*Online
9) 大森智弘, 他 : BNP (brain natriuretic peptide) の検討で明らかになったメーカー間差. 臨床検査 55 : 928-942, 2011.
 
10) 一ノ谷英憲, 他 : アーキテクトi2000SRとパスファーストを用いたBNP測定の比較検討. 日本臨床検査自動化学会会誌 38 (3) : 332-335, 2013.
Medical*Online
11) 吉田大輔, 他 : 全自動化学発光免疫測定装置ARCHITECTによるNT-proBNP 測定試薬の性能評価. 医療と検査機器・試薬 42 (1) : 43-49, 2019.
Medical*Online
12) 船附賢三, 他 : BNP測定試薬における国内評価検討の実施. Rinsho Byori 67 : 1103-1108, 2019.
 
13) Nishiyama K, et al : Relationship between biological variation in B-type natriuretic peptide and plasma renin concentration in stable outpatients with dilated cardiomyopathy. Circ J 75 (8) : 1897-1904, 2011.
 
14) Nishiyama K, et al : Biological variation of brain natriuretic peptide and cardiac events in stable outpatients with nonischemic chronic heart failure. Circ J 75 (2) : 341-347, 2011.
PubMed
15) McMurray JJ, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (11) : 993-1004, 2014.
PubMed
16) Packer M, et al : Comparison of omapatrilat and enalapril in patients with chronic heart failure : the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (8) : 920-926, 2002.
PubMed
17) 蔦本尚慶 : 心不全バイオマーカーとしてのナトリウム利尿ペプチドの歴史と展望. 医学と薬学 76 (10) : 1457-1473.
Medical*Online
18) Packer M, et al : Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (1) : 54-61, 2015.
PubMed
19) 宮本康平, 他 : 全自動化学発光免疫測定装置ARCHITECTによるNT-proBNP測定試薬の基礎性能評価. 医学と薬学 77 (1) : 81-90, 2020.
Medical*Online
20) Ibrahim NE, et al : Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. J Am Coll Cardiol 73 (11) : 1273-1284, 2019.
PubMed
P.1063 掲載の参考文献
1) Anderson HJ, Churchill-Davidson HC, Richardson AT : Bronchial neoplasm with myasthenia ; prolonged apnoea after administration of succinylcholine. Lancet 265 (6799) : 1291-1293, 1953.
PubMed
2) Lambert EH, Eaton LM, Rooke ED : Defect of neuromuscular conduction associated with malignant neoplasm. Am J Physiol 187 : 612-613, 1956.
 
3) Lang B, Newsom-Davis J, Wray D, et al : Autoimmune aetiology for myasthenic (Eaton-Lamberton) syndrome. Lancet 2 : 224-226, 1981.
 
4) Newsom-Davis J, Murray N, Wray D, et al : Lambert-Eaton myasthenic syndrome electrophsiological evidence for a humoral factor. Muscle Nerve 5 (95) : S17-S20, 1982.
 
5) Roberts A, Perera S, Lang B, et al : Paraneoplactic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 317 : 737-739, 1985.
 
6) Lang B, Newsom-Davis J, Peers C et, al : The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J Physiol 390 : 257-270, 1987.
 
7) Catterall WA : Signaling complexes of voltage-gated sodium and calcium channels. Neurosci Lett 486 : 107-116, 2010.
PubMed
8) Leys K, Lang B, Johnston I, et al : Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neurol 29 : 307-314, 1991.
PubMed
9) 本村政勝, 末永章人, 松尾秀徳, 他 : Lambert-Eaton myasthenic syndromeにおける電位依存性カルシウムチャネル自己抗体. 臨床神経 34 : 980-984, 1994.
 
10) M Motomura, I Johnston, B Lang, et al : An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58 : 85-87, 1995.
 
11) Lennon VA, Kryzer TJ, Griemann GE, et al : Calcium-channel antibodies in the Lambert Eaton syndrome and other paraneoplastic syndrome. N Engl J Med 332 : 1467-1474, 1995.
 
12) Motomura M, Lang B, Johnston I, et al : Incident of serum anti-P/Q type and anti N type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147 : 35-42, 1997.
 
13) Lindstrom J, Campbell M, Nave B : Specificities of antibodies to acetylcholine receptors. Muscle Nerve 1 : 140-145, 1978.
PubMed
14) 本村政勝, 中尾洋子, 福田卓, 他 : 放射性免疫測定法による血清P/Q型電位依存性カルシウムチャネル抗体測定-LEMSキットの基礎的及び臨床的検討-. Neuroimmunology 9 (2) : 233-238, 2001.
 
15) Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome : study of 110 Japanese patients. Neurology : 59 (11) : 1773-1775, 2002.
PubMed
16) 本村政勝 : 神経筋接合部の障害. 日本内科学会雑誌 97 (8) : 18-23, 2008.
 
P.1076 掲載の参考文献
1) 平成29年度・第51回臨床検査精度管理調査結果報告書 [免疫血清検査装置]
 
2) 石原香織, 宇野直輝, 柳原克紀, 他 : 肝炎およびレトロウイルス測定試薬8 項目を用いた全自動化学発光免疫測定装置Alinity(R) i の日常検査への導入検討. 医学と薬学 76 (4) : 511-516, 2019.
Medical*Online
P.1086 掲載の参考文献
1) Warren JR, Marshall B : Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1 (8336) : 1273-1275, 1983.
PubMed
2) INTERNATIONAL AGENCY FOR RESEARCH ON CANCER : Schistosomes, Liver Flukes and Helicobacter pylori. IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS 61 : 177-240, 1994.
 
3) 浅香正博 : ピロリ菌除菌による胃がん予防はどこまで可能か?. 臨牀と研究 95 (2) : 146-149, 2018.
Medical*Online
4) Ford AC, Forman D, Hunt RH, et al : Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals. BMJ 348 : g3174, 2014.
PubMed
5) 「ヘリコバクター・ピロリ感染の診断及び治療に関する取扱いについて」の一部改正について. 保医発0221第31号 平成25年2月21日.
 
6) 加藤智惠子, 杉山敏郎 : Helicobacter pyloriの感染診断と除菌判定. 日本消化器病学会雑誌 112 : 994-999, 2015.
Medical*Online
7) 徳永健吾, 渡辺一宏, 田中昭文, 他 : Helicobacter pylori除菌判定における13C-尿素呼気試験の有用性と問題点. 日本消化器病学会雑誌 102 : 176-182, 2005.
Medical*Online
8) 千葉隆士, 加藤勝章, 只野敏浩, 他 : 臨床診断のための便中 H. pylori抗原検査の検査精度の検討. 第25回 日本ヘリコバクター学会学術集会プログラム・抄録集 : 94, 2019.
 
9) H Ohkuma, K Abe, Y Kosaka, et al : Detection of luciferase having two kinds of luminescent colour based on optical filter procedure : application to an enzyme immunoassay. Luminescence 15 (1) : 21-27, 2000.
 
10) N Kajiyama, E Nakano : Thermostabilization of firefly luciferase by a single amino acid substitution at position 217. Biochemistry 32 (50) : 13795-13799, 1993.
 
11) N Kajiyama, E Nakano : Enhancement of thermostability of firefly luciferase from Luciola lateralis by a single amino acid substitution. Biosci Biotechnol Biochem 58 (6) : 1170-1171, 1994.
 
12) H Tatsumi, S Fukuda, M Kikuchi : Construction of biotinylated firefly luciferases using biotin acceptor peptides. Anal Biochem 243 (1) : 176-180, 1996.
 
13) 加藤勝章 : 宮城県対がん協会がん検診センター. 日本消化器内視鏡学会雑誌 56 (4) : 1621-1624, 2014.
 
14) 中甫 : 測定法の検出限界の求め方. Medical Technology 18 : 1041-1045, 1990.
 

書評

最近チェックした商品履歴

Loading...